ES2189213T3 - Utilizacion de un compuesto de tipo retinoide para aumentar in vivo la actividad de desacoplamiento de la proteina ucp2. - Google Patents

Utilizacion de un compuesto de tipo retinoide para aumentar in vivo la actividad de desacoplamiento de la proteina ucp2.

Info

Publication number
ES2189213T3
ES2189213T3 ES98936435T ES98936435T ES2189213T3 ES 2189213 T3 ES2189213 T3 ES 2189213T3 ES 98936435 T ES98936435 T ES 98936435T ES 98936435 T ES98936435 T ES 98936435T ES 2189213 T3 ES2189213 T3 ES 2189213T3
Authority
ES
Spain
Prior art keywords
activity
vivo
increase
decooplation
type compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98936435T
Other languages
English (en)
Inventor
Frederic Bouillaud
Daniel Ricquier
Zueco Eduardo Rial
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Centre National de la Recherche Scientifique CNRS
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Centre National de la Recherche Scientifique CNRS filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Application granted granted Critical
Publication of ES2189213T3 publication Critical patent/ES2189213T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Utilización de un compuesto de tipo retinoide para la preparación de un medicamento capaz de aumentar la actividad desacopladora de las proteínas UCP2.
ES98936435T 1997-08-05 1998-08-05 Utilizacion de un compuesto de tipo retinoide para aumentar in vivo la actividad de desacoplamiento de la proteina ucp2. Expired - Lifetime ES2189213T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9710009A FR2767058B1 (fr) 1997-08-05 1997-08-05 Utilisation d'un compose de type retinoide, notamment l'acide retinoique pour la preparation d' un medicament destine au traitement de l'obesite.

Publications (1)

Publication Number Publication Date
ES2189213T3 true ES2189213T3 (es) 2003-07-01

Family

ID=9510039

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009801680A Expired - Fee Related ES2147519B1 (es) 1997-08-05 1998-08-05 Utilizacion de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteina ucp2.
ES98936435T Expired - Lifetime ES2189213T3 (es) 1997-08-05 1998-08-05 Utilizacion de un compuesto de tipo retinoide para aumentar in vivo la actividad de desacoplamiento de la proteina ucp2.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES009801680A Expired - Fee Related ES2147519B1 (es) 1997-08-05 1998-08-05 Utilizacion de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteina ucp2.

Country Status (9)

Country Link
US (2) US20030229143A1 (es)
EP (1) EP1018338B1 (es)
AT (1) ATE228362T1 (es)
AU (1) AU8543098A (es)
CA (1) CA2299270A1 (es)
DE (1) DE69809785T2 (es)
ES (2) ES2147519B1 (es)
FR (1) FR2767058B1 (es)
WO (1) WO1999007358A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576906B1 (en) 1999-10-08 2003-06-10 Symyx Technologies, Inc. Method and apparatus for screening combinatorial libraries for semiconducting properties
WO2001035096A2 (en) * 1999-11-10 2001-05-17 Mitokor Diseases associated with altered mitochondrial function
US6365796B1 (en) 2000-02-16 2002-04-02 Beth Israel Deaconess Medical Center Transgenic UCP2 knockout mouse and use thereof
WO2001075131A2 (en) * 2000-03-31 2001-10-11 University Technology Corporation Expression of uncoupling protein (ucp) in plants
US7105718B2 (en) 2000-03-31 2006-09-12 The Regents Of The University Of Colorado Compositions and methods for regulating metabolism in plants
ES2177404B1 (es) * 2000-07-07 2004-09-16 Consejo Superior De Investigaciones Cientificas Procedimiento para la determinacion de la actividad de las proteinas desacoplantes (ucps) mediante la monitorizacion del consumo de nad (p) h.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051449A (en) * 1991-02-27 1991-09-24 Kligman Albert M Treatment of cellulite with retinoids
US5219888A (en) * 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
TW272187B (es) * 1992-05-20 1996-03-11 Hoffmann La Roche
US5457129A (en) * 1993-05-17 1995-10-10 Research Development Foundation Inhibition of nitric oxide production by retinoic acid
WO1995018533A1 (en) * 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Methods and compounds affecting adipocyte differentiation and obesity
FR2723315B1 (fr) * 1994-08-02 1996-10-25 Cird Galderma Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes
US5489611A (en) * 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
FR2735367B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Utilisation de ligands specifiques des recepteurs rxrs
KR19990045756A (ko) * 1995-09-18 1999-06-25 윌리암 엘. 레스페스 Ｒｘｒ 작용제를 이용하는 ｎｉｄｄｍ 치료 방법

Also Published As

Publication number Publication date
US20030229143A1 (en) 2003-12-11
FR2767058A1 (fr) 1999-02-12
DE69809785T2 (de) 2003-09-18
US20070015830A1 (en) 2007-01-18
WO1999007358A1 (es) 1999-02-18
EP1018338B1 (en) 2002-11-27
ES2147519A1 (es) 2000-09-01
AU8543098A (en) 1999-03-01
CA2299270A1 (en) 1999-02-18
FR2767058B1 (fr) 2000-05-05
EP1018338A1 (en) 2000-07-12
DE69809785D1 (de) 2003-01-09
ES2147519B1 (es) 2001-03-16
ATE228362T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
BR9808348A (pt) Alimento medicinal para diabéticos
BR9816013A (pt) Proteìna de ligação de interleucina-18
DK0509317T3 (da) Lægemidler imod knoglesygdomme
DE59009175D1 (de) Endoskop für die nasale Chirurgie.
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
PT730864E (pt) Medicamento para tratar doencas inflamatorias cardiacas
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
BR9714200A (pt) Análogos de hormÈnio paratiróide
ATE466106T1 (de) Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen
LU93259I2 (fr) LETIFEND (Protein Q)
ATE493978T1 (de) Behandlung von autoimmunerkrankungen
EA199700380A1 (ru) Бициклические ароматические соединения, фармацевтическая и косметическая композиции на их основе и применение косметической композиции
PT87523A (pt) Mischkristalle aus insulin und insulinderivaten verfahren zur herstellung dieser mischkristalle diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
ES2189213T3 (es) Utilizacion de un compuesto de tipo retinoide para aumentar in vivo la actividad de desacoplamiento de la proteina ucp2.
BR9913337A (pt) Derivados tan-1057
BR9804921A (pt) Peptìdeo natriurético atrial (anp) como um aditivo para soluções de diálise peritoneal.
DE60107888D1 (de) Beta-Interferon zur Behandlung von Immunerkrankungen
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
ATE317021T1 (de) Antisense modulierung von lfa-3
IT1290828B1 (it) Uso di proteine estraibili da organi animali per la preparazione di medicamenti per il trattamento di condizioni patologiche
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
DE69000791D1 (de) Therapeutische mittel fuer metabolische knochenkrankheiten.
PT878195E (pt) Utilizacao de um composto 2-aroil-3-arilbenzo(b)tiofeno para a reducao de fibrinogenio